Welcome to the New Mexico Chapter of the American College of Cardiology
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Please join your cardiology colleagues at the ACC Rockies Chapter Meeting in Park City, Utah for updates on ACC affairs, the potential new CV Board, and clinical topics such as Genetic and Sports EP, plus a discussion on the growing role of obesity medications in heart failure, and the first-ever Cardiology State-of-the-State report. There will be many opportunities for networking, as well!.
For more information and to register, please visit: 
Latest in Cardiology from ACC.org
- New Global Burden of CVD Report Shows Wide Variation Among CountriesCardiovascular disease remains the leading cause of disease burden, causing one in three deaths worldwide, according to the latest Global Burden of Disease study report published Sept. 24 in JACC and presented during a special side event as part of the 80th Session of the United Nations General Assembly in New York.
- OASIS 4: Significant Weight Loss With Oral Semaglutide Comparable With High-Dose, SC VersionsOral semaglutide 25 mg once daily was associated with significant weight loss vs. placebo, comparable with that seen with the 50 mg oral dose and with the subcutaneous (SC) injectable version of the drug, according to new results from the phase 3 OASIS 4 trial, published Sept. 17 in NEJM.
- Metoprolol Versus Aficamten in Patients With Left Ventricular Outflow Tract Obstruction on Exercise Capacity in HCMThe MAPLE-HCM trial showed that, among patients with symptomatic obstructive HCM, aficamten monotherapy was superior to metoprolol monotherapy in improving peak oxygen uptake and hemodynamics, and decreasing symptoms.
- A Study of Mavacamten in Nonobstructive Hypertrophic CardiomyopathyAmong patients with nonobstructive HCM in the ODYSSEY-HCM trial, mavacamten failed to significantly improve peak oxygen uptake or improve health status compared with placebo.
- ATTAIN-1: Oral Orforglipron Significantly Reduces Weight, Cardiometabolic RiskOrforglipron, a small-molecule, nonpeptide oral GLP-1 receptor agonist, at multiple doses produced significant weight loss and improved cardiometabolic risk factors compared with placebo, according to the phase 3 ATTAIN-1 trial, presented at the European Association for the Study of Diabetes General Assembly 2025 and simultaneously published Sept. 16 in NEJM.